HER2 targeted therapies for cancer and the gastrointestinal tract

Keyphrases

• Gastrointestinal Tract 100%
• Human Epidermal Growth Factor Receptor 2 (HER2) 100%
• HER2-targeted Therapy 100%
• Inhibitory Activity 40%
• Mucositis 40%
• Anticancer Drugs 20%
• In Cancer 20%
• Nausea 20%
• Leukemia 20%
• Possible Mechanisms 20%
• Vomiting 20%
• Diarrhea 20%
• Monoclonal Antibody 20%
• Epidermal Growth Factor Receptor Family 20%
• Receptor Tyrosine Kinase 20%
• Drug Class 20%
• Epidermal Growth Factor Receptor 20%
• Abdominal Pain 20%
• Gastrointestinal Damage 20%
• Gastrointestinal Toxicity 20%
• Small Molecule Tyrosine Kinase Inhibitors 20%
• ErbB2 20%
• Targeted Therapy Drugs 20%
• Viral Oncogenes 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Epidermal Growth Factor Receptor 66%
• Mucosa Inflammation 66%
• Pharmacotherapy 33%
• Nausea and Vomiting 33%
• Diarrhea 33%
• Monoclonal Antibody 33%
• Protein Tyrosine Kinase 33%
• Anticarcinogen 33%
• Abdominal Pain 33%
• Gastrointestinal Toxicity 33%
• Protein Tyrosine Kinase Inhibitor 33%
• Erythroleukemia 33%